Moore Capital Management’s Clovis Oncology, Inc. CLVS Stock Holding History

Moore Capital Management’s Portfolio CLVS Stock Details CLVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-25,000	Closed	-$1.14M	–	358
2018 Q2	$1.14M	Hold	25,000	–	–	0.03%	210
2018 Q1	$1.32M	Hold	25,000	–	–	0.03%	184
2017 Q4	$1.7M	Sell	25,000 -5,000	-17%	-$350K	0.03%	190
2017 Q3	$2.47M	Buy	30,000 +20,000	+200%	+$1.59M	0.05%	151
2017 Q2	$936K	Sell	10,000 -30,000	-75%	-$1.84M	0.03%	162
2017 Q1	$2.55M	Buy	+40,000	New	+$2.43M	0.07%	148
2016 Q4	–	Sell	-95,000	Closed	-$3.42M	–	302
2016 Q3	$3.42M	Buy	+95,000	New	+$2.04M	0.12%	115

Other funds holding CLVS

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Moore Capital Management's CLVS Position: Q3 2018 in Review

Moore Capital Management sold out of Clovis Oncology, Inc. (CLVS) in Q3 2018, closing a stake of 25,000 shares — an estimated $1.14M sold.

Moore Capital Management first reported a position in CLVS in Q3 2016 and held it in 7 quarters. The position peaked at $3.42M in Q3 2016. 192 funds tracked by Wall St. Rank hold CLVS as of Q3 2018.

Moore Capital Management reported no remaining Clovis Oncology, Inc. position as of Q3 2018 after selling out during the quarter.
Moore Capital Management sold 25,000 Clovis Oncology, Inc. shares in Q3 2018, an estimated $1.14M.
Moore Capital Management first reported a position in Clovis Oncology, Inc. in Q3 2016 and held it in 7 quarters.
Moore Capital Management's Clovis Oncology, Inc. position peaked at $3.42M in Q3 2016.
192 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q3 2018.

Based on Moore Capital Management's 13F filing for Q3 2018, filed 14 Nov 2018.